Roivant Sciences (ROIV) Net Margin (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Net Margin came in at 1737.12% in Q4 2024, up 269369.0% YoY from N/an in Q1 2024, and up 280.43% on a QoQ basis from 962.75% in Q3 2024.
Roivant Sciences (ROIV) Net Margin (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 5 years of Net Margin data on file, last reported at 1737.12% in Q4 2024.
- Quarterly Net Margin rose 269369.0% year-over-year to 1737.12% in Q4 2024, while the trailing twelve-month figure through Sep 2025 was 1256.56% (up 171034.0% YoY) and the FY2025 annual result came in at 1284.5%, up 224787.0% from the prior year.
- Net Margin improved to 1737.12% in Q4 2024, from 962.75% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 1737.12% in Q4 2024 to a low of 8191.34% in Q2 2022.
- A 5-year average of 2026.85% and a median of 1516.12% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin slumped 688458 bps — and 2023, when it soared 667522 bps.
- Tracing ROIV's Net Margin over 5 years: stood at 4792.99% in 2020, then surged by 71 bps to 1373.78% in 2021, then slumped by 126 bps to 3110.55% in 2022, then surged by 69 bps to 956.57% in 2023, then soared by 282 bps to 1737.12% in 2024.
- The last three Net Margin figures came in at 1737.12% (Q4 2024), 962.75% (Q3 2024), and 1115.06% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -20,152.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20,152.98% |
| Dec 31, 2024 | 1,737.12% |
| Sep 30, 2024 | -962.75% |
| Jun 30, 2024 | 1,115.06% |
| Dec 31, 2023 | -956.57% |
| Sep 30, 2023 | -2,360.22% |
| Jun 30, 2023 | -1,516.12% |
| Dec 31, 2022 | -3,110.55% |
| Sep 30, 2022 | -2,520.71% |
| Jun 30, 2022 | -8,191.34% |
| Dec 31, 2021 | -1,373.78% |
| Sep 30, 2021 | -1,613.21% |
| Jun 30, 2021 | -1,306.76% |
| Dec 31, 2020 | -4,792.99% |
| Sep 30, 2020 | -4,043.69% |
| Jun 30, 2020 | -506.15% |